Panthenol

Summary

Panthenol (CHEMBL1371937) is an approved small molecule; indicated across 4 conditions including common cold and influenza.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 4 conditions
• Clinical trials: 4
• Chemistry: 205.25 Da · C9H19NO4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1371937
Name	Panthenol
Type	Small molecule
Max phase	3
FDA approved	yes
PubChem CID	4678
Molecular formula	C9H19NO4
Molecular weight	205.25
InChIKey	SNPLKNRPJHDVJA-UHFFFAOYSA-N

SMILES: CC(C)(CO)C(C(=O)NCCCO)O

IUPAC name: 2,4-dihydroxy-N-(3-hydroxypropyl)-3,3-dimethylbutanamide

Also known as: NSC-759899, Pantenol, Panthenol, racemic, SID56320906, PANTHENOL, SID144212977

Patent coverage: 22,895 distinct patent families (59,391 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Beta-lactamase.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P00811	5.25	Potency	5623	nM	CHEMBL_ACT_4653332

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
common cold	3	MONDO:0005709	EFO:0007214
influenza	3	MONDO:0005812	EFO:0007328
respiratory system disorder	3	MONDO:0005087	EFO:0000684

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE3	3
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01531517	PHASE3	TERMINATED	Study of the Efficacy of PedyPhar® Ointment on the Diabetic Foot Ulcers
NCT01533220	PHASE3	COMPLETED	Efficacy of Nasal Naphazoline Hydrocloride + Pheniramine Maleate + Panthenol Compared With Naphazoline Hydrocloride in the Symptomatic Control of Nasal Congestion and Nasopharyngeal
NCT02379468	PHASE3	COMPLETED	Efficacy & Safety of Pedyphar Ointment in Diabetic Foot Ulcer Treatment
NCT05588973	Not specified	UNKNOWN	Prevention of Radiodermatitis in Breast and Head and Neck Cancer Patients in Cyprus

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).